Seeking Alpha

Abbott Laboratories (ABT)

()

News & PR
Market Currents

Buzz
Twitter: ABT

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Facet Rebuffs Biogen: Will a White Knight Emerge?

Dec 21 • EP Vantage • 1 Comment
2010's Dividend Aristocrats

Dec 14 • David I. Templeton • 4 Comments
Change in the Tone of the Markets

Dec 8 • Jeffrey Saut • 8 Comments
Top Dividend Stocks to Accumulate Now

Dec 2 • Dividend Growth Investor • 32 Comments
Sell-Side Is Complacent in the Face of Dubai

Dec 1 • First Coverage • Comment!
Health Care Takes Bigger Slice of Risk Capital

Nov 30 • Sydney Williams • Comment!
Why Should You Own Dividend-Paying Stocks?

Nov 30 • David Hunkar • 5 Comments
8 HealthCare Stocks with 3%+ Dividends

Nov 29 • Hao Jin • 9 Comments
Abbott Acquires Global Rights to Chronic Pain Treatment

Nov 24 • Zacks.com • Comment!
Saut: Expect More Upside, Driven by Underinvested Institutional Investors

Nov 24 • Jeffrey Saut • 5 Comments
Diabetes Care: Global Investing Opportunities

Nov 22 • Mike Havrilla • 4 Comments
Winning Investment Strategy: Focus on Value-Based Dividend Growth

Nov 18 • Dividends4Life • 5 Comments
Will Questions over Cholestorol Drug Zetia Create a Major Setback for Merck?

Nov 17 • Zacks.com • Comment!
Direction of Cholesterol Debate Could Benefit Abbott Labs

Nov 16 • EP Vantage • 1 Comment
Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck

Nov 16 • Derek Lowe • Comment!
Wall Street Breakfast: Must-Know News

Nov 16 • Suzanne Miller • 35 Comments
Dividend Achievers: How Have They Performed?

Nov 15 • Dividend Inc • 12 Comments
Big Pharma Willing to Pay for Biotech Innovation

Nov 15 • The Burrill Report • Comment!
7 Dividend Stocks to Prove Buy-and-Hold Isn't Dead

Nov 11 • Dividends4Life • 42 Comments
D.C. Vaccine Conference: Why Investors Should Stay Tuned

Nov 9 • M. E. Garza • Comment!
How Are the S&P's Dividend Aristocrats Performing?

Nov 5 • David I. Templeton • 8 Comments
The Entry Point Market Investors May Be Missing

Nov 4 • Amit Chokshi • 9 Comments
Abbott Laboratories: Dividend Stock Analysis

Oct 26 • Dividends4Life • 3 Comments
8 Dividend Stocks with Wide Moats

Oct 21 • Dividends4Life • 31 Comments
Biotech: Q3 Market Update

Oct 16 • R. Scott Raynovich • 1 Comment
Equities Update: Earnings Power

Oct 14 • Midnight Trader • 5 Comments
Wednesday Options Recap

Oct 14 • Frederic Ruffy • Comment!
Abbott Q3: Outperforms and Raises Guidance

Oct 14 • Zacks.com • Comment!
Good Debt Coverage for Sustainable Dividends

Oct 14 • Dividend Growth Investor • 4 Comments
Earnings Preview: Abbott Labs

Oct 13 • theflyonthewall.com • Comment!
This Week's Market: Breaking Out or Topping Out?

Oct 13 • David Brown • 4 Comments
Columbus Day Dash and Slash: DepoMed, Vivus, Oncolytics and RadNet

Oct 12 • M. E. Garza • 1 Comment
Options Trader Weekly Review: Not Such a Good Week

Oct 11 • Philip Davis • Comment!
10 Dividend Stocks to Buy Now

Oct 9 • Dividend Inc • 22 Comments
The 10 Best U.S. Dividend Stocks

Oct 7 • Dividends4Life • 42 Comments
Buying Dividends: Next Week's Ex-Div Stocks

Oct 6 • Stockerblog • 6 Comments
'Survivor's Bounce' Coming to an End

Oct 4 • Rising Dividend Investing • 4 Comments
Capital Markets Open Up to Biotechs

Oct 4 • The Burrill Report • Comment!
Abbott Records a 35% Reduction in Oil and Gas Usage

Oct 1 • Greentech Media • 5 Comments
34 Safe Dividend Stocks; 9 Criteria to Select Them

Oct 1 • FXedu • 2 Comments
When 'Event Risk' Is a Good Thing

Sep 29 • optionMONSTER • Comment!

Abbott Laboratories (ABT)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers